AGLE
Aeglea BioTherapeutics Inc

Chart
Stats
Earnings
News
Splits
Dividends
Earnings
Actual EPS |
---|
Consensus EPS |
Estimated EPS |
Number of Estimates |
EPS Surprise |
Stats
Summary
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. In the second quarter of 2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families.
Market Cap: 31.4 Million
Primary Exchange: NASDAQ
Website: aegleabio.com
Shares Outstanding: 61.5 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.498700396423222
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags

Longest drawdown: 2490 trading days
From: 2016-04-08 To: 2023-01-27
Lowest Point:
Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
---|
Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
---|